Mednet Logo
Community

When evaluating for PMRT in patients who did not receive neoadjuvant chemotherapy and are found to be pN0, do you utilize clinical T-staging, or pathologic T-staging?

For example, if preoperative imaging indicates T3 disease (non-mass enhancement extending over 5cm) but final pathology s/p mastectomy shows multiple foci of disease less than 5 cm (pT1-2), would you offer PMRT? Are there any other factors that you would consider?
1 Answer
Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Allegheny Health Network, Pittsburgh
Answered on

If no neoadjuvant therapy, I rely on the pathologic staging rather than clinical staging for PMRT decisions.

So, for a cT3 that is a pT1-2, I would not offer PMRT. I do consider factors including receptor status, margins status, LVSI, and age.

Join for free or sign in to see the full answer